Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 1, 2016, Pages 47-53

  Kongtim, Piyanuch ^a,b   Popat, Uday ^a   Jimenez, Antonio ^a   Gaballa, Sameh ^a   El Fakih, Riad ^a   Rondon, Gabriela ^a   Chen, Julianne ^a   Bueso Ramos, Carlos ^a   Borthakur, Gautam ^a   Pemmaraju, Naveen ^a   Garcia Manero, Guillermo ^a   Kantarjian, Hagop ^a   Alousi, Amin ^a   Hosing, Chitra ^a   Anderlini, Paolo ^a   Khouri, Issa F ^a   Kebriaei, Partow ^a   Andersson, Borje S ^a   Oran, Betul ^a   Rezvani, Katayoun ^a   Marin, David ^a   Shpall, Elizabeth J ^a   Champlin, Richard E ^a   Ciurea, Stefan O ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Allogeneic stem cell transplantation; Chronic myelomonocytic leukemia; Hypomethylating agents; Myeloproliferative neoplasms; Secondary acute myeloid leukemia

Indexed keywords

AZACITIDINE; BUSULFAN; CLOFARABINE; CYTARABINE; DECITABINE; FLUDARABINE; HYDROXYUREA; IDARUBICIN; MELPHALAN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; ADOLESCENT; ALLOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADENINE NUCLEOTIDES; ADOLESCENT; ADULT; AGED; ALLOGRAFTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84952638929     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.08.031     Document Type: Article

References (35)

1. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, International Agency for Research on Cancer, Lyon, France. 4th ed.
2. Elliott M.A., Tefferi A., Hogan W.J., et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006, 37:1003-1008.
3. Kerbauy D.M., Chyou F., Gooley T., et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005, 11:713-720.
4. Krishnamurthy P., Lim Z.Y., Nagi W., et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant 2010, 45:1502-1507.
5. Kröger N., Zabelina T., Guardiola P., et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002, 118:67-73.
6. Laport G.G., Sandmaier B.M., Storer B.E., et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008, 14:246-255.
7. Mittal P., Saliba R.M., Giralt S.A., et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 2004, 33:1005-1009.
8. Ocheni S., Kroger N., Zabelina T., et al. Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant 2009, 43:659-661.
9. Eissa H., Gooley T.A., Sorror M.L., et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 2011, 17:908-915.
10. Adekola K., Popat U., Ciurea S.O. An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors. Bone Marrow Transplant 2014, 49:1352-1359.
11. Such E., Cervera J., Costa D., et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011, 96:375-383.
12. Berman E., Wiernik P., Vogler R., et al. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer 1997, 80(Suppl. 11):2181-2185.
13. Nazha A., Kantarjian H., Ravandi F., et al. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients
14. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
15. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
16. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2009, 15:367-369.
17. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
18. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
19. Cox D. Regression models and life tables (with Discussion). J R Stat Soc 1972, 34:187-200.
20. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
21. Worsley A., Oscier D.G., Stevens J., et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988, 68:17-21.
22. del Cañizo M.C., Sanz G., San Miguel J.F., et al. Chronic myelomonocytic leukemia-clinicobiological characteristics: a multivariate analysis in a series of 70 cases. Eur J Haematol 1989, 42:466-473.
23. Fenaux P., Jouet J.P., Zandecki M., et al. Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol 1987, 65:101-106.
24. Beran M., Wen S., Shen Y., et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymph 2007, 48:1150-1160.
25. Onida F., Kantarjian H.M., Smith T.L., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002, 99:840-849.
26. Mufti G.J., Stevens J.R., Oscier D.G., et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985, 59:425-433.
27. Bacher U., Haferlach T., Kern W., et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 2005, 84:250-257.
28. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
29. Adès L., Sekeres M.A., Wolfromm A., et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 2013, 37:609-613.
30. Aribi A., Borthakur G., Ravandi F., et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007, 109:713-717.
31. Braun T., Itzykson R., Renneville A., et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011, 118:3824-3831.
32. Costa R., Abdulhaq H., Haq B., et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011, 117:2690-2696.
33. Fianchi L., Criscuolo M., Breccia M., et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymph 2013, 54:658-661.
34. Garcia-Manero G., Gore S.D., Cogle C., et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011, 29:2521-2527.
35. Wong E., Seymour J.F., Kenealy M., et al. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymph 2013, 54:878-880.